Therapeutics Acquisition Corp.
Completed 2021-06-30- CIK 1811764
- TXAC
- Now PNT
- IPO 2020-07-09
- $136M trust
- 285 filings
Successfully merged with POINT Biopharma Inc. • Now trading as PNT
- IPO Size
- $136M
- raised at the IPO
- Trust
- $136M
- as of 2021-03-31
- Current Status
- Completed
- from its latest filing
- IPO Year
- 2020
- year it listed
Filings, by quarter
285 filings over 16 quarters; violet bars carry a milestone
- 20 Q2: 7 filings
- 20 Q3: 28 filings
- 20 Q4: 1 filing
- 21 Q1: 13 filings
- 21 Q2: 53 filings
- 21 Q3: 25 filings
- 21 Q4: 9 filings
- 22 Q1: 27 filings
- 22 Q2: 15 filings
- 22 Q3: 19 filings
- 22 Q4: 9 filings
- 23 Q1: 11 filings
- 23 Q2: 12 filings
- 23 Q3: 4 filings
- 23 Q4: 51 filings
- 24 Q1: 1 filing
- S-1 filed 20 Q2
- IPO 20 Q3
- Definitive agreement 21 Q1
- Completed 21 Q2
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
About
Therapeutics Acquisition Corp. is a blank-check company seeking an initial business combination, with a stated focus on the healthcare industry and an emphasis on biotechnology. Its proposed business purpose is to acquire an operating business through a merger or similar combination.
Investment Focus
Healthcare, Biopharmaceuticals
Geographic Focus
United States
Key Information
As the filings state it
- IPO Date
- 2020-07-09
- Total Redemptions
- $13.9M
- PIPE
- $165M
- SIC
- 6770
- Completion Date
- 2021-06-30
- Merger Target
- POINT Biopharma Inc.
- SPAC Ticker
- TXAC
- Merged Ticker
- PNT
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
The team is led by RA Capital founder and managing partner Peter Kolchinsky and RA Capital principal Matthew Hammond, with directors experienced in biotech entrepreneurship and operating leadership, biopharmaceutical finance, and biotechnology company executive management. RA Capital is a life-sciences-focused investment firm with extensive healthcare and biotechnology investment experience.